Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering

Abstract:
WestPark Capital, Inc. announced the initial closing of a private placement for Arrogene NanoTechnology, Inc. on January 10, 2012. A total of 500,000 Units, each Unit consisting of one share of common stock and two common stock purchase warrants, were sold, generating gross proceeds of approximately $500,000. Proceeds from the offering will be used for working capital and research and development related to Arrogene's diagnostic and therapeutic technologies for brain, breast and lung cancer. WestPark Capital, Inc. acted as placement agent for the offering.

WestPark Capital, Inc. Announces $500,000 Arrogene NanoTechnology, Inc. Offering

Los Angeles, CA | Posted on January 20th, 2012

This news release does not constitute an offer to sell or the solicitation of offers to buy any security and shall not constitute an offer, solicitation, or sale of any security in any jurisdiction in which such offer, solicitation, or sale would be unlawful. The offering was made only by Confidential Private Placement Memorandum. Copies of the Confidential Private Placement Memorandum may be obtained via written request to WestPark Capital, Inc., 1900 Avenue of the Stars, Suite 310, Los Angeles, California 90067.

####

About WestPark Capital, Inc.
WestPark Capital is a leading investment banking and securities brokerage firm serving the needs of private and public growth companies worldwide. WestPark is committed to forging lasting partnerships with emerging growth companies and the investors who back them. WestPark provides a comprehensive range of corporate finance services, including initial public offerings, follow-on offerings, private placements and corporate finance advisory services. Additional information about WestPark Capital, Inc. is available at www.wpcapital.com or at . Member: FINRA/SIPC

About Arrogene NanoTechnology, Inc.

Arrogene NanoTechnology is developing a new generation of diagnostic and therapeutic drugs based on a new family of nano-biopolymers. Arrogene was founded in 2007 to commercialize a new cancer targeting technology and a proprietary molecular delivery platform that interferes with cancer targets to inhibit and finally eradicate tumor progression. Additional information about Arrogene is available at www.arrogene.com.

For more information, please click here

Contacts:
WestPark Capital, Inc.
Richard Rappaport, CEO
(310) 843-9300

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

VC/Funding/Angel financing/Loans/Leases/Crowdfunding

Harris & Harris Group Portfolio Company OpGen Raises $17.1 Million in Initial Public Offering May 6th, 2015

News and information

The next step in DNA computing: GPS mapping? May 6th, 2015

Improving Clinical Care and Patient Quality of Life in Advanced Liver Disease, d-LIVER Workshop, Milan, 27 May 2015 May 6th, 2015

Grafoid Acquires MuAnalysis Inc; Expands Its Advanced Materials Testing Capabilities May 6th, 2015

Winner Announced for NNI’s First ‘EnvisioNano’ Nanotechnology Image Contest May 6th, 2015

Nanomedicine

A better way to build DNA scaffolds: McGill researchers devise new technique to produce long, custom-designed DNA strands May 6th, 2015

Thermometer-like device could help diagnose heart attacks May 6th, 2015

Improving Clinical Care and Patient Quality of Life in Advanced Liver Disease, d-LIVER Workshop, Milan, 27 May 2015 May 6th, 2015

Arrowhead Completes Dosing Healthy Volunteers and Initiates Transition to Patients in Phase 1 Study of ARC-AAT May 5th, 2015

Announcements

The next step in DNA computing: GPS mapping? May 6th, 2015

Improving Clinical Care and Patient Quality of Life in Advanced Liver Disease, d-LIVER Workshop, Milan, 27 May 2015 May 6th, 2015

Grafoid Acquires MuAnalysis Inc; Expands Its Advanced Materials Testing Capabilities May 6th, 2015

Winner Announced for NNI’s First ‘EnvisioNano’ Nanotechnology Image Contest May 6th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project